U.S. biotech companies attracted a bountiful $1.3 billion venture haul in the fourth quarter of 2013, pushing the total for the year to $4.53 billion--well ahead of 2012's mark of $4.19 billion and a hopeful sign of continued activity headed into 2014.
David Blech, the long dethroned "King of Biotech," will spend the next three years in a low-security prison in Fort Dix, NJ, after a federal appeals court tossed out claims that the judge presiding over his case had been biased against him.
Amazon founder and new media mogul Jeff Bezos is investing a bit of his personal fortune in Seattle-based Juno Therapeutics, a biotech startup that's been making some big waves in the immunotherapy world.
Since setting up shop in 2006, WellDoc has financed development of its mobile diabetes management tool through debt and angel investment, snagging itself the input of pharma veterans in the process. Now, it has landed its first round of institutional investment, with Merck Global Health Innovation Fund and others committing $20 million.
California's Atara Biotherapeutics has heaped more cash onto its second funding round, giving the Amgen spinoff $52 million in Series B funds to support its programs in kidney disease and oncology.
Canadian biotech Clementia Pharmaceuticals has closed a $22.5 million A round led by OrbiMed and licensed in a drug from Roche it plans to develop for a rare bone disorder called fibrodysplasia ossificans progressiva.
German billionaire Dietmar Hopp is adding to his multimillion-dollar wager on AC Immune, the Swiss biotech that is playing a key role in some high-profile Alzheimer's programs.
Elliott Sigal has opened the next chapter of his career. The former R&D chief at Bristol-Myers Squibb, who helped squire a number of blockbuster programs through the clinic, is joining David Mott as a venture partner at New Enterprise Associates.
Blueprint Medicines has completed a $25 million round of Series B financing to pursue its patient-focused vision of developing tailored, genomic-specific cancer treatments.
Close to a decade after a pair of investigators from Baylor College of Medicine launched Bellicum Pharmaceuticals in Houston, the biotech has added $14.7 million to its Series B round, which will help expand an ongoing Phase I/II study of its lead therapy for graft vs. host disease.